Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2005
08/23/2005US6933276 Methods of treating peripheral neuropathies using neurotrophin-3
08/23/2005US6933275 Protein kinase C peptides for use in withdrawal
08/23/2005US6933274 Methods for treatment of diabetes using a peptide analogues of insulin
08/23/2005US6933273 Nucleotide sequences coding polypeptide for use as wound healing agent
08/23/2005US6933271 Aimed at neoplastic cells with gonadotropin releasing hormone binding sites; anticarcinogenic agents; genetically engineered Pseudomonas Exotoxin
08/23/2005US6933142 Mammalian glycosylsulfotransferases expressed in high endothelial cells (HEC-GLCNAC6ST) and polypeptides coded by nucleic acids, used for medical diagnosis, drug screening and therapy
08/23/2005US6933133 Treatment of diabetes with synthetic beta cells
08/23/2005US6933132 Regulation of immune responses by attractin
08/23/2005US6933125 Human c-Maf compositions and methods of use thereof
08/23/2005US6933113 Modulation of endogenous gene expression in cells
08/23/2005US6933108 Treating viral disease in mammals; administer viricide to mammal, monitor activity of virus, reduced viral activity indicates effective viricide
08/23/2005US6932977 Method of inducing or enhancing chondrogenesis with extracellular matrix containing BMP-4
08/23/2005US6932973 Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration
08/23/2005US6932968 An anti-idiotype antibody against the binding region of an antibody directed against an EPO peptide, wherein said antibody neutralizes the bioactivity of EPO; diagnostic aids for the detection of EPO or of anti-EPO antibodies
08/23/2005US6932965 Separation of deamidated and non-deamidated human dnases and use of the non-deamidated species as a pharmaceutical per se; administering to patients suffering from pulmonary distress
08/23/2005US6932777 Prophylactic and therapeutic treatment of the ductal epithelium of a mammary gland for cancer
08/23/2005CA2267661C Variants of vascular endothelial cell growth factor having antagonistic properties
08/23/2005CA2266884C Inhibition of 26s and 20s proteasome by indanones
08/23/2005CA2172508C Method for preparing microspheres comprising a fluidized bed drying step
08/23/2005CA2119006C Composition and method of treating hepatitis c
08/23/2005CA2094464C Mutant respiratory syncytial virus (rsv) vaccines containing same and methods of use
08/23/2005CA2094276C Antibodies against the urokinase receptor and their use
08/23/2005CA2070281C Improved treatment of autoimmune diseases by aerosol administration of auto antigens
08/18/2005WO2005076003A2 Diagnostics and therapeutics for diseases associated with plasma glutamate carboxypeptidase (pgcp)
08/18/2005WO2005076001A2 A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual
08/18/2005WO2005075685A1 Genes associated with canine osteoarthritis and related methods and compositions
08/18/2005WO2005075672A1 Diagnostics and therapeutics for diseases associated with human cholecystokinin receptor b (cckbr)
08/18/2005WO2005075666A2 Diagnostics and therapeutics for diseases associated with puromycin sensitive aminopeptidase npepps (npepps)
08/18/2005WO2005075665A2 Diagnostics and therapeutics for diseases associated with plasma kallikrein (klkb1)
08/18/2005WO2005075648A1 Interleukin-18 mutant proteins
08/18/2005WO2005075646A1 Peptide originating in stress-induced antiapoptosis molecule (iex-1)
08/18/2005WO2005075641A1 Screening method
08/18/2005WO2005075635A2 Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
08/18/2005WO2005075630A2 New acylglycerol acyltransferase-like proteins dc4 and uses thereof
08/18/2005WO2005075512A1 Crystal structures and models for fc receptors and uses thereof in the design or identification of fc receptor modulator compounds
08/18/2005WO2005075511A1 Variants of the extracellular domain of bcma and uses thereof
08/18/2005WO2005075510A1 Diagnostics and therapeutics for diseases associated with potassium channel, subfamily k, member 9 (kcnk9)
08/18/2005WO2005075505A1 Peptides that antagonize fpr class receptor mediated signaling
08/18/2005WO2005075501A1 Polyoxyalkylene compound and method for making
08/18/2005WO2005075436A2 Novel inhibitors of glutaminyl cyclase
08/18/2005WO2005075414A1 Peptidyl arginine deiminase type iv inhibitor
08/18/2005WO2005075004A1 Method and apparatus for organ regeneration and method of screening drug promoting organ regeneration
08/18/2005WO2005074996A2 Lat1 transporter expressed in blood brain barrier cells
08/18/2005WO2005074991A1 Antitumor agent
08/18/2005WO2005074985A2 Methods of modulating cd200 and cd200r
08/18/2005WO2005074981A2 Inhibitors of tgf-r signaling for treatment of cns disorders
08/18/2005WO2005074980A1 Treatment of neurodegenerative diseases by the use of gpr49
08/18/2005WO2005074979A1 Use of prourokinase for treating pte or crao
08/18/2005WO2005074978A1 Use of alkaline phosphatase for the detoxification of lps present at mucosal barriers
08/18/2005WO2005074977A1 Paraoxonase-containing pharmaceutical preparation
08/18/2005WO2005074976A1 Composition comprising polymeric material and uses thereof
08/18/2005WO2005074975A1 Use of factor viia factor for treating trauma
08/18/2005WO2005074974A1 Use of factor viia for treating late complications of trauma
08/18/2005WO2005074973A2 Method of inducing or modulating immune response
08/18/2005WO2005074972A2 Treatment of conditions involving dopaminergic neuronal degeneration using nogo receptor antagonists
08/18/2005WO2005074971A1 Treatment of neurodegenerative diseases by the use of cgi-13 interacting molecules
08/18/2005WO2005074970A2 Neuroprotective dietary supplement
08/18/2005WO2005074968A2 Medical use of basic peptides
08/18/2005WO2005074967A2 Progastrin derived peptides
08/18/2005WO2005074966A1 A method of modulating cellular uptake and molecules useful for same
08/18/2005WO2005074960A1 Physiologically functional drinks and compositions
08/18/2005WO2005074951A1 Compositions containing internally activated antioxidant
08/18/2005WO2005074916A1 Methods and compositions for the treatment of lipodystrophy
08/18/2005WO2005074903A2 Sulfhydryl protected glutathione prodrug
08/18/2005WO2005074896A1 Sustained release preparation
08/18/2005WO2005074892A1 The cream containing interferon liposome
08/18/2005WO2005074888A2 Replacement enzyme cochleates
08/18/2005WO2005074655A2 Materials and method for promotion of nerve regeneration
08/18/2005WO2005074650A2 Modified human four helical bundle polypeptides and their uses
08/18/2005WO2005074645A2 Methods and compositions for modulating angiogenesis
08/18/2005WO2005074633A2 Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
08/18/2005WO2005074626A2 Compositions, methods and uses for a novel family of peptides
08/18/2005WO2005074579A2 Peptide mixtures with immunomodulatory activity
08/18/2005WO2005074556A2 Netrin compositions and methods of use thereof
08/18/2005WO2005074546A2 Modified human growth hormone polypeptides and their uses
08/18/2005WO2005074524A2 Modified human interferon polypeptides and their uses
08/18/2005WO2005074381A2 Induction of apoptosis via arts-iap complexes
08/18/2005WO2005060996A3 Method of altering the pka type i signalling pathway
08/18/2005WO2005058939A3 Methods and compositions for inhibition of bcl6 repression
08/18/2005WO2005058369A3 Compositions of l-caldesmon for treating viral infection
08/18/2005WO2005056760A3 Glycopegylated follicle stimulating hormone
08/18/2005WO2005056037B1 Metered dose inhalation preparations of proteins and peptides
08/18/2005WO2005055930A3 Recombinant factor viii having increased specific activity
08/18/2005WO2005054236B1 Substituted quinolines for the treatment of cancer
08/18/2005WO2005045041A3 Rna interference mediated inhibition of cholesteryl ester transfer protein (cetp) gene expression using short interfering nucleic acid (sina)
08/18/2005WO2005044984A3 Modulators of the abc transporter family and methods for their use
08/18/2005WO2005044197A3 Synthesis of glycopeptides with superior pharmacokinetic properties
08/18/2005WO2005042048A3 Bioactive hydrogel compositions for regenerating connective tissue
08/18/2005WO2005039485A3 Gsk-3 inhibitors and uses thereof
08/18/2005WO2005035003A3 Compositions and methods for increasing drug efficiency
08/18/2005WO2005032572A3 Means and methods for the recruitment and identification of stem cells
08/18/2005WO2005030794A3 Hemiasterlin derivatives and uses thereof
08/18/2005WO2005026741A3 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide
08/18/2005WO2005026206A3 Vegf-induced genes and their therapeutic use
08/18/2005WO2005023980A3 Use of complement protein c3 and its derivatives in enhancing mammalian embryo development
08/18/2005WO2005021065A3 Indirect delivery of growth factors into the central nervous system
08/18/2005WO2005014619A3 Heparin-binding peptides and uses thereof
08/18/2005WO2005013899A3 Compositions and methods for the therapy and diagnosis of lung cancer
08/18/2005WO2005010044A3 Il-17 a/f heterologous polypeptides and therapeutic uses thereof
08/18/2005WO2005007854A3 Polycationic compositions for cellular delivery of polynucleotides
1 ... 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 ... 3163